Muhammad Furqan
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Muhammad Furqan sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
Muhammad Furqan: 3 sponsored US clinical trials, 1 recruiting.
Muhammad Furqan sponsors 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Extensive-stage Small-cell Lung Cancer, with 1 trials.
Upper-quartile sponsor footprint
Muhammad Furqan sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
3 total, page 1 of 1
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
NCT04699838
Use Peripheral Blood Proteomics to Predict the Treatment Response and Toxicities in NSCLC Immunotherapy
NCT03951012
Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer
NCT02769832
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
Therapeutic Areas
What is open in the Muhammad Furqan pipeline
1 recruiting of 3 indexed (33% open); 1 completed (33%).
Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).
Top condition: Extensive-stage Small-cell Lung Cancer (1 trial), 0 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Muhammad Furqan: open-pipeline peers nationwide
Peers matched on 3 registered trials and 33% open enrollment, not the therapeutic-area sidebar.
Muhammad Furqan sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 trials (± recruiting share)
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors near 33% open enrollment (± trial volume)
- Aadi Bioscience · 33% recruiting · 9 trials
- Aaron Cook · 33% recruiting · 3 trials
- Abivax S.A. · 33% recruiting · 6 trials
- Actuated Medical · 33% recruiting · 3 trials
Related
What to do with this Muhammad Furqan page
3 registered trials is a research-attention snapshot, not an endorsement of Muhammad Furqan or any single study.
- 1 of Muhammad Furqan's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Extensive-stage Small-cell Lung Cancer is the condition Muhammad Furqan studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Extensive-stage Small-cell Lung Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Muhammad Furqan pipeline card: 3 registered trials from official public datasets.Report a data error.